RE: RE: Open Market for 4601\!There is an intense commercial interest in mutated KRAS market. No one can come close to what 4601 can offer. Another fact. 4601 is close to showing the world that it can more effective than Victobix and Erbitux for normal KRAS cancer and for mutated KRAS.
No one come close to 4601, but at the same time 4601 is close to show superiority????
Do you see how stupid you are freakin takeover lobster?
The fact is that the actual GBM trial is not on selected patients with mutated KRAS. So nothing will be proven with this trial. So nothing is close. In fact, the fastest way to maybe prove somenthing about 4601 and mutated KRAS would be a stoppage of the GBM trial in September, due to unconvincing results, and the start of a new trial in an other application with that time selected patients with the KRAS mutation. This is a real possiblitiy because now they have the money to make that choice.
Remember. They made that tax loss deal for a reason. They could have waited for interim results and they did not. Why???? This is the good question the takeover lobster is not asking. If spectacular interim results are coming, there was no need for that tax loss deal. Why was it done? To extend their autonomy, to gain flexibility. To allow them to continue the GBM trial for one more year with a low stock price, or to switch application with single valid candidate, 4601. So as you can see, this is very risky for the trapped lobsters!!!!! YUP YUP YUP YUP YUP YUP YUP YUP YUP YUP YUP YUP YUP YUP!!!!!!!!!!